Introduction
The incidence and mortality of hepatocellular carcinoma (HCC) are increasing, and HCC has emerged to be the second most common cause of cancer death worldwide [1, 2] . Although surveillance programs have improved, diagnosis of HCC is still made in advanced stages where treatment options are limited. Of note, during the last years, there have been research efforts leading to the development of immunotherapies targeting programmed cell death protein-1 showing promising efficacy [3] . However, currently, according to the current European Association for the Study of the Liver (EASL) and American Association for the Study of the Liver (AASLD) guidelines, the oral multi-tyrosine kinase inhibitor sorafenib is the only recommended systemic first-line treatment in patients with advanced HCC [4] [5] [6] [7] , but meanwhile further targeted therapies such as lenvatinib as a first-line treatment and regorafenib and cabozantinib in second/third-line treatments have demonstrated their efficacy [8, 9] . However, overall survival (OS) in these patients is still poor, and patients treated with sorafenib often show a high incidence of adverse events that worsen quality of life and often lead to dose reduction and even early cessation of sorafenib treatment [10, 11] . Therefore, alternative treatment options for patients with advanced HCC are urgently needed. Selective internal radiotherapy (SIRT) has shown early evidence of efficacy and better safety in HCC patients, therefore suggesting HCC radiosensitivity in a proportion of patients, but two phase 3 trials (SARAH and SIRveNIB) failed to demonstrate an advantage of SIRT compared to sorafenib [12, 13] .
During the last years, stereotactic body radiation therapy (SBRT) has emerged as an effective noninvasive treatment modality [14] [15] [16] [17] [18] [19] [20] . Although radiation therapy of liver tumors has historically been performed rarely and with mostly a short-term palliative Definitions HCC was diagnosed according to current guidelines by histopathology or computed tomography scan or dynamic contrast-enhanced magnetic resonance imaging showing the typical hallmark of HCC imaging (hypervascularity in the arterial phase with washout in the portal venous or delayed phases) [5, 22, 23] . The number of focal hepatic lesions, the maximum tumor diameter and portal vein thrombosis (PVT) and its extent were detected during contrast enhancement. The numbers of intrahepatic lesions are summarized in oligonodular (one or two intrahepatic lesions) and in multifocal HCC (three or more lesions or diffuse HCC growth pattern). HCC was staged according to the Barcelona Clinic Liver Cancer (BCLC) classification. Liver function was assessed using the Child-Pugh score.
SBRT Techniques
The analysis was performed on a multi-center SBRT database that was organized by the Working Group on Stereotactic Radiotherapy of the German Society of Radiation Oncology (DEGRO) on primary liver cancer. This database was designed as an SBRT patterns-of-care database within the DEGRO initiative and headed by the DEGRO Working Group on Stereotactic Radiotherapy. A detailed description of patient, tumor and treatment characteristics was collected retrospectively and collated in a tabular data structure. Most patients with advanced tumors were either ineligible or progressed after TACE or other treatments. Patients with BCLC stage C that progressed under sorafenib had no other treatment options. For patients (BCLC stage B) that progressed after TACE, SBRT was offered as a local ablative option, as an alternative to systemic therapy with sorafenib, which has a high toxicity profile. Furthermore, for patients with oligometastatic disease (BCLC stage C) there is emerging evidence that TACE, a local ablative treatment, significantly improves OS [24] . Taking these data into consideration, patients that progressed under TACE were also offered SBRT by the multidisciplinary tumor panel, as an alternative to systemic treatment.
The median number of fractions was 7 (range 3-12). Dose was prescribed most frequently to the 80% isodose (median) with an inhomogeneous dose profile as typical for SBRT treatments. Prescribed dose was available for all lesions. Planning target volumes (PTV) were chosen as surrogate tumor volumes which were available in all cases. The PTV was defined according to the institutional standards typically including the PVT when possible. Furthermore, in order to equate or compare the different fraction schedules, we converted the dose to biological effective dose (BED) [25] . In cases of multinodular disease, SBRT was performed either simultaneously or sequentially depending of the size of the PTV and the dose 700 cm 3 of the uninvolved liver and the Child Pugh score, according to Pan et al. [26] . Motion management was categorized into simple (free breathing, abdominal compression) versus advanced (breath-hold, gating, tracking). For lesions where dose constraints for the OARs according to Timmermann [27] could not be achieved due to small overlaps with the PTV, a more moderate fractionation as well as a simultaneous integrated protection dose prescription was employed instead of reducing the dose to the entire PTV as described elsewhere [28] . In cases where the dose constraints for the liver which depended on the size of the lesion or the Child Pugh score or for the other organs at risk could not be achieved, these patients were considered ineligible for SBRT.
Importantly, some patients with extrahepatic disease received SBRT of the extrahepatic lesions (adrenal metastases [n = 1] or palliative radiotherapy of the bone metastases [n = 5]). Moreover, 33 patients who progressed after SBRT received further HCC treatment consisting of sorafenib in 20 patients (16.4%), TACE in 11 patients (9.0%) and TACE and sorafenib in 2 patients (1.6%).
Sorafenib Treatment and Toxicity
Sorafenib treatment was initiated after multidisciplinary discussion as the first tumor therapy or in patients who had relapse, failure or ineligibility to surgical or locoregional treatments. After initiation of sorafenib therapy, patients were followed-up after 4 weeks and thereafter every 3 months. During follow-up, safety and tolerability were reviewed. The cause for cessation of sorafenib treatment due to progressive disease, death, toxicity or patient preference was recorded. The occurrence of adverse events was recorded and graded according to the Common Toxicity Criteria Adverse Events (CTCAE, version 4.0). Treatmentassociated toxicity was defined as occurrence of adverse events after the beginning of SBRT or sorafenib treatment.
Ethics Approval
This study was performed in accordance with the Declaration of Helsinki and it has been approved by the local ethics committee of the University Hospital of Freiburg (No. EK 595/17).
Statistical Analyses
Baseline characteristics of the patients were analyzed before sorafenib treatment or SBRT, respectively. The primary outcome in our analysis was OS and treatment-associated toxicity was defined as the secondary endpoint. Continuous variables are expressed as mean with standard deviation, whereas categorical variables are reported as frequencies and percentages unless stated otherwise. For continuous variables, differences were determined using Wilcoxon-Mann-Whitney and Kruskal-Wallis tests as there was no Gaussian distribution of the data confirmed by the Kolmogorov-Smirnov test. χ 2 tests or Fisher's exact tests were used for categorical variables. p values < 0.05 were considered significant.
OS was defined from the day of initiation of sorafenib or SBRT treatment until death or last follow-up. At the end of the observation period (01/09/2017), 814 patients (78.6%) in the whole cohort and 128 patients (67.4%) in the matched cohort had died. Progression-free survival (PFS) was defined from the day of starting sorafenib or SBRT treatment until death or radiological progression. Data concerning PFS were available in 786 of 1,023 patients (76.8%) (sorafenib group: 680 of 901 patients [75.5%], SBRT group: 106 of 122 patients [86.9%]). OS and PFS were calculated using Kaplan-Meier analyses, and they are reported as median OS or PFS with the corresponding 95% confidence interval (95% CI). Differences in OS were assessed using log rank tests and uni-and multivariable Cox regression models (forward selection method with likelihood ratio). Propensity score matching was performed to reduce selection bias for the allocation to sorafenib or SBRT. Multivariable logistic regression model was performed to generate the propensity score. The following factors were included in this model: Child-Pugh score, prior surgery, radiofrequency ablation, TACE, hepatic tumor burden, PVT, extrahepatic metastases, and ECOG performance status (PS) (ECOG PS 0 vs. 1 vs. 2). After establishing the propensity score, 1: 1 matching using the nearest-neighbor matching was performed with a caliper of 0.01 without replacement. Post hoc balance diagnostic was performed using mean standardized differences [29] .
Statistical analyses were performed with SPSS (version 24.0, IBM, New York, NY, USA) GraphPad Prism (version 6, GraphPad Software, San Diego, CA, USA) and STATA (version 15, StataCorp Lp, College Station, TX, USA). Table 1 summarizes the baseline characteristics of the patient cohorts treated with sorafenib and SBRT. In the unmatched cohort, significantly more patients treated with sorafenib presented with multifocal HCC compared to SBRT patients (76.6 vs. 46.7%, p < 0.001). PVT was also more frequently observed in patients treated with sorafenib (34.0 vs. 18.0%, p < 0.001). A total of 35.7% of the sorafenib patients had extrahepatic metastases compared to 13.1% of SBRT patients (p < 0.001). In summary, sorafenib patients presented with more advanced tumor disease compared to SBRT patients, which is also underlined by higher BCLC stages in sorafenib-treated patients.
Results

Patient and Treatment Characteristics
In the sorafenib group, the mean treatment duration was 5.7 ± 6.7 months. In 522 patients (57.9%), sorafenib was applied with the recommended dose of 800 mg per day, and in 379 patients (42.1%) a reduced dose was given.
In patients with SBRT, the median prescribed SBRT dose was 44 (range: 21-66) Gy in 3-12 fractions with a median maximum dose (D max ) of 58 (range: 26-72) Gy. The median BED (BED 10 ) prescribed was 84.4 (range: 36-124) Gy.
Toxicity
Adverse Events in the Sorafenib Cohort Overall, 73.6% (663/901) of sorafenib-treated patients experienced at least one sorafenib-associated adverse event at any grade (Table 2) . A total of 39.3% developed diarrhea, 31.2% showed hand-foot skin reaction, 29.3% developed fatigue, 19.0% had significant weight loss, 13.3% developed sorafenib-related hypertension. Mucositis occurred in 4.7%, and 7.5% of the sorafenib-treated patients reported nausea and vomiting. Sorafenib was stopped in 175 patients (19.4%) due to adverse events. Data concerning dose reduction were available in 888 patients (98.6%), and of these 277 patients had dose reduction due to clinically significant adverse events (31.2%). In addition, sorafenib was stopped due to progressive HCC (53.8%), death (45.2%), patient preference (2.8%), and other reasons (6.2%). At the end of the observation period, 23 patients (2.6%) still received sorafenib.
Adverse Events in the SBRT Cohort Three SBRT patients with known portal hypertension developed gastric ulcers with bleeding, 3, 4 and 5 months after SBRT and were treated with proton pump inhibitors (2 patients, CTCAE grade 2) and transfusion (1 patient, grade CTCAE 3). The patient with CTCAE grade 3 gastroduodenitis who required a transfusion was treated in the past with liver SBRT for another HCC lesion, with an interval of 4 months between the two treatments. In all other cases, the constraints did not exceed the constraints proposed by Timmerman [27] . An increase in the Child-Pugh score without progression was observed in 4 patients (B7-B8, A6-B7, B8-C9, A5-A6), and 1 patient developed an increase of ≥2 points after treatment (A6-B8) due to a radiation-induced liver disease. This patient recovered fully from radiation-induced liver disease, but died 9 months after SBRT due to renal failure. One of these patients, with an increase of 1 point (A5-A6) died due to liver decompensation without tumor progression 4 months after SBRT, and 1 patient developed a liver decompensation and was transplanted without evidence of tumor disease (pathological complete response). One patient developed a necrotic abscess in the PTV of the liver due to a dislocation of a preexisting stent of the bile duct, and 1 patient developed a cholangitis probably deemed to be SBRT-related by the investigators. We did not observe any higher incidence of toxicities with higher doses, as different dose-fractionation schedules (Table 1) were used in order to respect the dose constraints for the organs at risk. Data are presented as n (%), mean ± SD or median (range). ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer; PVT, portal vein thrombosis; SBRT, stereotactic body radiation therapy; TD, total prescribed dose; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; BED 10,TD , biological equivalent dose of the prescribed dose; D max , maximum point dose; BED 10,max , biological equivalent dose of the maximum point dose. a Patients may have received more than one treatment.
OS and PFS in Patients Treated with SBRT Compared to Sorafenib in the Unmatched and Matched Cohort
In patients treated with sorafenib, OS was 8.8 (8.2-9.5) months compared to 17.0 (9.8-24.2) months in the SBRT cohort. PFS was 4.0 (3.5-4.5) months in sorafenib-treated patients compared to 9.0 (5.2-12.7) months in SBRT patients (p < 0.001). We performed multivariable logistic regression model for development of the propensity score (online suppl. Table 1 ; for all online suppl. material, see www.karger.com/doi/10.1159/000490260). After 1: 1 matching using the nearest-neighbor method, we identified 190 patients (95 sorafenib patients and 95 SBRT patients) with comparable patient and tumor characteristics (Table 3) . Covariates which were used for development of the propensity score showed mean standardized differences ≤0.01 indicating adequate balance of the matched variables.
In the matched cohort, patients treated with SBRT still had improved OS of 16.0 (11.0-21.0) months compared to 9.6 (8.6-10.7) months in the sorafenib group (p = 0.005, Fig. 1a ). After matching, PFS was 6.0 (4.8-7.2) months in patients with sorafenib compared to 9.0 (5.8-12.2) months in SBRT patients (p = 0.004, Fig. 1b) .
Thirty-three patients (27.0%) who were treated with SBRT showed progression during the study period and received further treatment (sorafenib: n = 20, TACE: n = 11, TACE and sorafenib: n = 2) which may have affected OS. In order to adjust for this confounder, we excluded these patients and were able to reproduce the survival benefit of SBRT treated patients (online suppl. Fig. 1) .
Further, we performed uni-and multivariate Cox regression analyses and confirmed SBRT as an independent positive prognostic factor for OS (Table 4; 
OS in Patients with Extrahepatic Metastases and PVT in Patients Treated with Sorafenib or SBRT
We further performed subgroup analyses in patients with PVT (n = 328) and extrahepatic metastases (n = 338). In the unmatched cohort, patients with extrahepatic metastases treated with SBRT (only SBRT of the hepatic tumor) showed a significantly improved OS compared to patients with sorafenib treatment (16. Fig. 2a) . Importantly, some patients with extrahepatic disease received SBRT of these extrahepatic lesions (adrenal metastases [n = 1] and palliative radiotherapy of Data are presented as n (%) or mean ± SD. ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer; PVT, portal vein thrombosis; SBRT, stereotactic body radiation therapy; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein. a Patients may have received more than one treatment.
the bone metastases [n = 5]). These patients were not included in the matched cohort due to the lack of an adequate matching partner.
Patients with PVT treated with SBRT had a median OS of 8.0 (4.3-11.7) compared to 6.1 (5.2-6.9) months in sorafenib-treated patients in the unmatched cohort (p = 0.330). After propensity score matching, there was no difference concerning OS between patients with SBRT or sorafenib treatment (9.0 [2.9-15.1] vs. 6.0 [2.7-9.3] months, p = 0.568, Fig. 2b ).
Discussion
HCC is often diagnosed in intermediate or advanced tumor stages [5, 30] . Especially in advanced tumor stages, treatment options are limited, and there is no consensus concerning the best treatment option according to the current NCCN guidelines [31] . However, sorafenib is recommended in these patients according to the current EASL, AASLD and European Society for Medical Oncology (ESMO) guidelines [6, 32, 33] . Sorafenib is associated with many adverse events as shown in our study which may lead to a significant deterioration of quality of life. Moreover, the development of adverse events during sorafenib treatment is associated with application of a reduced dose of sorafenib [11, 34, 35] . In our study, only 57.9% of the patients were treated with the recommended dose of 800 mg per day, and 31.2% of the patients had dose reduction. Taken together, there is a need for a well-tolerable treatment strategy in patients with advanced HCC. During the last years, there have been many research efforts leading to immunotherapies targeting programmed cell death protein-1 with nivolumab, and these treatment approaches showed promising results in HCC patients with few adverse events [36, 37] . The efficacy of these therapies in direct comparison to sorafenib is still under investigation and is not yet clarified (NCT 02576509). However, the main limitation of these immunotherapeutic approaches is that only 20% of the patients showed an objective tumor response, and to date there are no biomarkers available to select those patients who will benefit most from immunotherapies.
SBRT has emerged as an effective and safe treatment approach, even in patients with advanced liver disease with acceptable toxicity [14, 17, 18, 20, 38, 39] without compromising quality of life [40, 41] . Recently, it has been suggested that SBRT is as effective as radiofrequency ablation [42] and TACE [43] in selected patients. Moreover, SBRT has shown good efficacy in local control of HCC lesions as a bridging therapy to liver transplantation [44] [45] [46] [47] . However, there have been no studies focusing on the efficacy of SBRT in comparison to sorafenib in advanced HCC, and the combination of both was correlated with a higher incidence of adverse events [48] . In order to answer this important clinical question, we analyzed an international, multicenter HCC database with patients treated with sorafenib and a German/Swiss cohort of SBRT patients. In our unmatched cohort, patients treated with sorafenib presented with more advanced tumor disease as shown by a higher prevalence of PVT, extrahepatic metastases, and also more extensive hepatic disease. Moreover, significantly more patients were classified as BCLC A in the sorafenib group, although in this BCLC stage, sorafenib is not recommended by the current HCC guidelines. These observations are in line with the GIDEON study showing that, especially in Asia, patients were significantly more often treated with sorafenib in BCLC A stages [35] . These patients also had multiple prior HCC treatment including several TACE sessions. Indeed, after several embolization procedures, further transarterial approaches may be limited due to impaired vascular architecture so that sorafenib is also used in this setting although the patient is formally classified as having an earlier BCLC stage [49] .
As patients allocated to sorafenib treatment versus to SBRT show different baseline tumor and patient characteristics which may directly affect OS and PFS and therefore lead to a significant bias, we performed a propensity score matching to adjust for these confounders. The significant survival benefit of patients treated with SBRT compared to sorafenib patients in the unmatched cohort was also reproducible after propensity score matching.
Importantly, patients with advanced tumor disease are very heterogeneous as they may show PVT and/or extrahepatic metastases, and it needs to be clarified if both patient groups show the same survival benefit when treated with SBRT compared to sorafenib. Patients with extrahepatic metastases who were treated with SBRT of the intrahepatic HCC nodules (excluding radiation therapy of the extrahepatic metastases as these patients were not included in the matched analyses) showed significantly improved OS compared to patients who were treated systemically with sorafenib alone. This finding is in line with our previous results showing that intrahepatic tumor control with TACE is associated with improved OS compared to sorafenib treatment [24, 50] . Moreover, rare events such as abscopal effects on metastases after local tumor therapy have been described in other tumor entities and also in cases of HCC as the SBRT can modulate antitumor immune responses [51] [52] [53] [54] [55] [56] [57] [58] [59] . As we did not focus on the changes of extrahepatic metastases in our study, we cannot answer this question. However, in summary, our results may provide the rationale for treating intrahepatic HCC with SBRT also in patients with extrahepatic metastases.
In comparison to patients with extrahepatic metastases, we were not able to confirm a survival benefit in patients with PVT treated with SBRT compared to sorafenib treatment. We only observed a trend to a better OS which may be due to the reduced sample size after propensity score matching. In this setting, selective internal radiation therapy (SIRT) has shown good efficacy in several studies [60, 61] . However, in the recently published SARAH trial, sorafenib tended to be superior to SIRT in patients with PVT. However, considering all patients, SIRT was not able to show superior OS compared to sorafenib [12] . Taken together, due to the controversial results, further studies have to evaluate the efficacy of SBRT in comparison to sorafenib and SIRT in well-powered prospective and randomized trials.
We have to acknowledge limitations of our study. It was a retrospective, observational study and therefore treatment allocation was not controlled and may be biased due to different factors such as the intrahepatic tumor burden, liver function, and especially the PS of the patient. Especially the PS of the patients and the toxicities are difficult to assess retrospectively. Furthermore, it is difficult to overcome the institutional differences of the treatment decision policies in patients with advanced or recurrent HCCs after prior treatments. In order to equate or compare the different fraction schedules, we converted the dose to BED, which was similar to the published literature (ranging between 33.6 and 103 Gy in the study of Bujold et al. [62] ) which did not correlate with OS (data not shown).
Further, we tried to adjust for these differences by propensity score matching. As we applied strict matching criteria with a caliper of 0.01, our sample size in the matched cohort was significantly reduced compared to the unmatched cohort. The small sample size may especially limit the conclusions, which can be drawn from our subgroup analyses. We were
